Ophthalmology · Bethlehem, PA
NPI
1346202330
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
1530 8th Ave, Suite 102
Bethlehem, PA, 18018
Phone (610) 691-3335
Groups this clinician bills Medicare through
Medicare paid, 2024
$202K
4,291 services
Medicare patients, 2024
1,070
Average age 77
Drug cost, 2024
$1.2M
3,765 prescriptions
Company payments, 2025
$949
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Eugene M Saravitz Jr. was code 92014 (ophthalmological e&m), 898 times for 813 patients. In total Eugene M Saravitz Jr. billed 4,291 services in 38 codes, and Medicare paid $202K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-08-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92014 Ophthalmological E&M | Office | 898 | 813 | $77.76 | $70K |
| 92012 Ophthalmological E&M | Office | 731 | 507 | $55.80 | $41K |
| 92083 Vision, Hearing, and Speech Services | Office | 486 | 447 | $39.30 | $19K |
| 92133 Computerized Ophthalmic Imaging | Office | 481 | 450 | $23.35 | $11K |
| 92020 Ophthalmological E&M | Office | 445 | 437 | $17.43 | $7,757 |
| 92202 Ophthalmological E&M | Office | 408 | 389 | $10.30 | $4,204 |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 291 | 89 | $46.91 | $14K |
| 99427 Chronic, Principal, and Transitional Care Management | Office | 120 | 64 | $35.70 | $4,284 |
| 92004 Ophthalmological E&M | Office | 116 | 116 | $87.94 | $10K |
| 92134 Computerized Ophthalmic Imaging | Office | 71 | 64 | $25.55 | $1,814 |
| 76514 Ultrasound - Nonspecific | Office | 54 | 48 | $7.43 | $401 |
| 66821 Cataract Surgery | Office | 41 | 34 | $217.69 | $8,925 |
| 92250 Angiography | Office | 36 | 36 | $22.03 | $793 |
| 67820 Eye | Office | 28 | 13 | $13.14 | $368 |
By year: 2022 $236K for 4,060 services; 2023 $196K for 3,919 services; 2024 $202K for 4,291 services.
Medicare prescription drug claims, 2024
In 2024, the drug Eugene M Saravitz Jr. prescribed most often to Medicare patients was Lumigan (Bimatoprost), with 916 prescriptions and refills. In total Eugene M Saravitz Jr. wrote 3,765 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Lumigan Bimatoprost | 916 | 2,159 | 252 | $530K |
| Latanoprost Generic | 606 | 1,397 | 171 | $7,490 |
| Brimonidine Tartrate Generic | 247 | 573 | 83 | $10K |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 240 | 516 | 57 | $4,894 |
| Combigan Brimonidine Tartrate/Timolol | 190 | 450 | 59 | $104K |
| Alphagan P Brimonidine Tartrate | 141 | 321 | 44 | $74K |
| Timolol Maleate Generic | 128 | 343 | 43 | $2,323 |
| Travoprost Generic | 116 | 270 | 35 | $33K |
| Dorzolamide Hcl Generic | 109 | 213 | 27 | $2,706 |
| Simbrinza Brinzolamide/Brimonidine Tart | 99 | 161 | 20 | $30K |
| Restasis Cyclosporine | 91 | 199 | 36 | $112K |
| Cyclosporine Generic | 89 | 187 | 36 | $58K |
| Prednisolone Acetate Generic | 86 | 174 | 41 | $4,229 |
| Brinzolamide Generic | 75 | 125 | 18 | $19K |
| Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol | 72 | 152 | 23 | $16K |
Brand drugs: 2,164 claims; generic drugs: 1,601 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Eugene M Saravitz Jr. $949 ($949 in general payments such as food, travel and fees) from 7 companies. The largest payer was Abbvie Inc. with $367.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 14 | $367 |
| Bausch & Lomb Americas Inc. BLCO | 2 | $215 |
| Alcon Vision LLC ALC | 8 | $188 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 2 | $130 |
| Dompe US, Inc. | 1 | $17.27 |
| Thea Pharma Inc. | 1 | $16.8 |
| Glaukos Corporation GKOS | 1 | $15.61 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.